Where is Novo Nordisk A/S (NVO) Headed?

Novo Nordisk A/S (NYSE:NVO) is one of the best affordable healthcare stocks to buy now. On December 22, Novo Nordisk A/S (NYSE:NVO) announced the FDA approval of the Wegovy^® pill, a once-daily oral semaglutide 25 mg, for long term weight management, excess body weight reduction, and reduction in the risk of major adverse cardiovascular events. The approval makes the Wegovy^® pill the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management.

In another development, Novo Nordisk A/S (NYSE:NVO) announced on December 18 the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-weekly CagriSema, which is a cagrilintide 2.4 mg and semaglutide 2.4 mg injection, for use with increased physical activity and a reduced-calorie diet for the reduction of excess body weight and maintenance of long term weight reduction in adults with obesity of overweight. CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and the GLP-1 receptor agonist, semaglutide 2.4 mg.

Management reported that if CagriSema  is approved, it would become the first injectable GLP-1 receptor agonist and amylin analogue combination treatment. It added that adults with obesity or overweight, with at least one obesity-related complication, lost an average of 23% body weight after taking CagriSema in the REDEFINE 1 phase 3 trial when evaluating the treatment effect if all patients stayed on treatment.

Novo Nordisk A/S (NYSE:NVO) further reported that the FDA is anticipated to review the CagriSema application in 2026, with the company continuing to build on its 100-year-plus legacy of innovation and science with potential new treatments in the obesity sphere.

Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products.

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.